Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
Infrastructure of Support
Cure, Deerfield’s Innovation Campus Deerfield Discovery & Development External Operations Genscience | Human Genetic Foresight
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Investment
Portfolio Oversight Healthcare Services Medical Technologies Therapeutics Business Development Public Structured Finance Trading
Deerfield Discovery & Development (3DC)
Deerfield Institute
Data Analytics and Development Information Research
Internal Operations
Administration Building Operations Finance Human Resources Legal and Compliance Information Technology
External Operations
Partnership & Communications
Featured
Deerfield Management Launches Joint Venture with Horizon Blue Cross Blue Shield of New Jersey Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund Deerfield Management Welcomes Frank Nestle, MD, FMedSci, as Partner and Chief Executive Officer of Therapeutic Discovery and Development
News by Type
Press Release Insights
News by Industry
Therapeutics Healthcare Services Medical Technologies Cross-industry
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Foundation Partners by Focus
Children's Health Diversity Initiatives Maternal Health View All
Founded Diversity Programs
Break into the Boardroom Fellowships Women in Science
---
Cure Campus

Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure
Explore the healthcare ecosystem

Deerfield Management Announces Winners of the First Annual XSeed Award

Grants will support five New York City-based early-stage life sciences startups, prioritizing historically underrepresented company founders

2021 XSeed Award focused on infectious diseases to continue to combat world health issues

(New York, NY, April 20, 2021)—Deerfield Management Company, a New York City-based healthcare investment firm, today announced the grant recipients of its XSeed Award, a new program designed to support early-stage life science startups. Each of the five New York City-based award winners, a majority of which were women or other underrepresented founders, will receive a $100,000 grant to further projects focused on infectious diseases.

The 2021 recipients of Deerfield’s inaugural XSeed Award are:

  • Dr. Chandrabali Ghose-Paul, Founder and CEO of Bioharmony Therapeutics, for her work with next-gen antimicrobial therapies for lethal, drug-resistant bacterial infections
  • Dr. Ashiwel Undieh, The City College of New York, for his work with platform nanotechnology for enhanced formulation and delivery of mRNA vaccines
  • Dr. Jonathan Lai, Albert Einstein College of Medicine, for his work with alphavirus-associated arthritis
  • Dr. Julie Magarian Blander, Professor of Immunology at Weill Cornell Medicine, for her work with pan-coronavirus vaccines
  • Dr. Andras Fiser, Dr. John Blanchard, Dr. Simone Sidoli, and Dr. Johanna Daily, all from  Albert Einstein College of Medicine, for their work to identify effective drug combinations for the treatment of K. pneumoniae

“This year has been unlike any other in so many ways, not the least of which is the unprecedented advancement of medical science,” said Joseph Pearlberg, MD, Ph.D., Vice President of Scientific Affairs at Deerfield. “Our inaugural group of XSeed Awardees will support some of New York City’s most talented researchers and scientists with a focus on developing cures for infectious diseases. As we begin to rebound from the pandemic, we cannot become complacent – support for new ideas and vaccines should remain a global priority.”

The XSeed Award was created by Deerfield as a result of the partnership announced in September 2019 between NYC Economic Development Corporation (NYCEDC) and Deerfield to develop the Cure life science campus. The 12-story vertical cam